SCHEMBL1330486

SCHEMBL1330486

Cc1cccc(NC(=O)Nc2cccc(-c3ccc4c(-c5cnn(C)c5)n[nH]c4c3)c2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.62
AXL P30530 9/20 0.62
FGFR1 P11362 4/20 0.57
DDR2 Q16832 1/20 0.57
NTRK1 P04629 3/20 0.56
MAP2K7 O14733 1/20 0.52
TTK P33981 1/20 0.51
MAPK8 P45983 1/20 0.51
CSF1R P07333 6/20 0.50
FLT1 P17948 6/20 0.50
KIT P10721 5/20 0.50
AURKA O14965 4/20 0.50
ROCK2 O75116 4/20 0.50
RPS6KB1 P23443 4/20 0.50
STK3 Q13188 4/20 0.50
ROCK1 Q13464 4/20 0.50
AURKB Q96GD4 4/20 0.50
PLK4 O00444 3/20 0.50
DYRK3 O43781 3/20 0.50
MAP4K4 O95819 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1332041 0.95 KDR (0.69) KDRAXLFGFR1DDR2NTRK1
SCHEMBL1330301 0.85 AXL (0.60) KDRAXLFGFR1DDR2NTRK1
SCHEMBL1331695 0.85 AURKB (0.61) KDRAXLFGFR1DDR2NTRK1
SCHEMBL1331637 0.84 KDR (0.64) KDRAXLFGFR1DDR2NTRK1
SCHEMBL1329799 0.83 KDR (0.66) KDRAXLFGFR1NTRK1MAP2K7
SCHEMBL1330237 0.83 FGFR1 (0.70) KDRAXLFGFR1DDR2NTRK1
SCHEMBL1330072 0.82 KDR (0.75) KDRAXLFGFR1NTRK1MAP2K7
SCHEMBL1331850 0.81 FGFR1 (0.64) AXLFGFR1DDR2NTRK1TTK
SCHEMBL1330136 0.81 AXL (0.62) KDRAXLFGFR1DDR2AURKB
SCHEMBL1331362 0.81 FGFR1 (0.62) KDRAXLFGFR1DDR2NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2569301-A1 INDAZOLE INHIBITORS OF KINASE Abbvie Inc. (US) 2013-03-20 EP disclosed
US-8293738-B2 Indazole inhibitors of kinase ABBOTT LABORATORIES (US) 2012-10-23 US disclosed
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE ABBOTT LABORATORIES (US) 2011-11-17 US disclosed
WO-2011143430-A1 INDAZOLE INHIBITORS OF KINASE ABBOTT LABORATORIES (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE AURKA, AURKC, AURKB KDR 11/4885AXL 399/4885FGFR1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.